Actually HGEN has been rather sparing on the PRs in comparison to most startup biotechs.
HGEN isn't a start-up biotech.
I would have never thought that even with vaccines out there people would be so hesitant to take them that the requirements for treatments would still be a pressing matter.
Huh? Everyone knew it was going to take time for vaccines to be rolled out and the U.S. is well ahead where anyone thought. Treatments won't be a pressing matter in the U.S. in a few weeks to a month and thus, HGEN (to the extent it gets EUA) is going to have to figure out how to get foreign countries to approve and buy its treatment. Everyone on this board keeps saying $10K per dose which is completely absurd.
Plus the imaging for the initial cancer results was promising so there is another application in the pipeline.